The clinical classification of renal tumors is being continuously refined based on the advances in morphological and molecular characterizations of novel and established renal tumor entities. Solid tumor molecular characterization efforts lead by various consortiums (CPTAC, TCGA) and select groups such as ours, have utilized next-generation sequencing and other high-throughput technologies to discover subtype-specific renal tumor molecular aberrations and biomarkers.